Kohjin Bio CoTSE:177A -0.90%18 ROE % is 1.67% as of Mar. 2026, which is 90% below its 10-year median of 17.42. GuruFocus rates TSE:177A with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 1,250 Biotechnology companies, Kohjin Bio Co ranks better than 82.24% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Kohjin Bio Co's annualized net income for the quarter that ended in Mar. 2026 was 円98 Mil. Kohjin Bio Co's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was 円5,879 Mil. Therefore, Kohjin Bio Co's annualized ROE % for the quarter that ended in Mar. 2026 was 1.67%.
The historical rank and industry rank for Kohjin Bio Co's ROE % or its related term are showing as below:
TSE:177A'
s ROE % Range Over the Past 10 Years
Min: 4.28 Med: 17.42 Max: 31.7
Current: 4.29
During the past 5 years, Kohjin Bio Co's highest ROE % was 31.70%. The lowest was 4.28%. And the median was 17.42%.
TSE:177A's ROE % is ranked better than 82.24% of 1250
companies
in the Biotechnology industry
Industry Median: -38.145
vs TSE:177A: 4.29
Kohjin Bio Co (TSE:177A) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Kohjin Bio Co ROE % Related Terms
Kohjin Bio Co ROE % Historical Data
* Premium members only.
The historical data trend for Kohjin Bio Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kohjin Bio Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kohjin Bio Co ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kohjin Bio Co's ROE % distribution charts can be found below:
* The bar in red indicates where Kohjin Bio Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Kohjin Bio Co (TSE:177A) has a ROE % of 1.67% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Kohjin Bio Co and its competitors. This is 90% below median its historical median of 17.42. Over the past decade, Kohjin Bio Co's ROE % has ranged from 4.28 to 31.70. According to the industry distribution chart, Kohjin Bio Co ranks #222 out of 1250 companies in the Biotechnology industry, placing it in the top 17.8%.
Is Kohjin Bio Co's ROE % too high?
Kohjin Bio Co's current ROE % of 1.67% is 90% below median its 10-year median of 17.42. Over the past 10 years, this metric has ranged from a low of 4.28 to a high of 31.70. Based on the distribution chart, Kohjin Bio Co ranks #222 out of 1250 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kohjin Bio Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Kohjin Bio Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kohjin Bio Co ranks #222 out of 1250 companies for ROE %. This places Kohjin Bio Co in the top 18% of its industry — outperforming the majority of peers. Historically, Kohjin Bio Co's own ROE % has ranged from 4.28 to 31.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Kohjin Bio Co and its competitors. Kohjin Bio Co's current ROE % is 1.67%, which is 90% below median its own 10-year median of 17.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kohjin Bio Co stock overvalued right now?
Kohjin Bio Co (TSE:177A) has a current ROE % of 1.67%. The current ROE % is 1.67%, which is 90% below median its 10-year median of 17.42. Kohjin Bio Co's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Kohjin Bio Co (TSE:177A), the current ROE % is 1.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kohjin Bio Co Ltd is engaged in development, manufacture and sale of culture media (growing environments used for culturing microorganisms and cells) and contract manufacturing of processed cell products. It has manufacturing and sales of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics.
18GF Score
Get the complete analysis for TSE:177A
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:177A has been successfully added to your 